BRCA1/2 Genetically Modified Breast Cancer Patients Effective in Breast Preservation Treatment
Jun 16, 2025
A study found that breast preservation treatment (baby breast preservation surgery + radiation therapy) is more effective in BRCA1/2 transgenic breast cancer patients compared to total mastectomy.
Professor Lee Jang-hee of Breast Surgery at Ewha Womans University Mokdong Hospital, Professor Yoo Jae-min of Breast Surgery at Samsung Medical Center, Professor Lee Sae-byeol of Breast Surgery at Asan Medical Center, and Professor Cha Chi-hwan of Breast Surgery at Hanyang University Hospital, research team led by the 'Long-term oncological outcome of breast-conservating treatment' of breast cancer patients with BRCA mutation It was announced in the May issue.
BRCA1/2 is a tumor suppressor gene that repairs DNA damage in our body, and it is known that mutations in these genes increase the risk of breast cancer. In addition, the mutation of the BRCA1/2 gene has a significant impact on the surgery and treatment of breast cancer.
Previously, Breast-Conservative Treatment (BCT) has become a standard treatment that can replace Mastectomy. However, for patients with BRCA1/2 gene mutations, the lack of safety evidence has pushed them to the back burner in the guidelines.
The study conducted this time conducted a multicenter retrospective cohort study to compare recurrence and survival rates according to surgical methods in high-risk breast cancer patients with BRCA1/2 gene mutations from 2008 to 2015.
The research team collected information on the clinical pathological characteristics and prognosis of 575 breast cancer patients (average age of 42 years) with BRCA1/2 gene mutations, and 389 (66.2%) of the patients included in the study underwent breast preservation treatment and 186 (33.8%) underwent total mastectomy.
Long-term follow-up of recurrence and survival rates between breast preservation treatment and total mastectomy groups showed no significant difference in zone recurrence and distant metastasis and overall recurrence rates in breast cancer recurrence. In addition, the group who underwent breast preservation treatment did not have a higher risk of death than the group who underwent total mastectomy, and multivariate analysis also showed that the surgical method did not affect the prognosis.
Professor Lee Jang-hee of surgery at Ewha Womans University Mokdong Hospital said, "This study is meaningful in that it proved the safety of breast preservation treatment for the first time in the world using propensity score matching (PSM) using statistical techniques in BRCA1/2 gene mutation patients collected from multiple organs in Korea. Various subgroup analysis including BRCA1/2 mutation type, tumor size, lymph node metastasis, histological grade also confirmed that breast preservation treatment can be considered as a breast cancer surgery method." he said.
He then said "This study is a retrospective cohort study, requiring further data collection and planning for prospective studies. Further research will be carried out to provide more accurate evidence in the future."
Professor Lee Jang-hee of Breast Surgery at Ewha Womans University Mokdong Hospital, Professor Yoo Jae-min of Breast Surgery at Samsung Medical Center, Professor Lee Sae-byeol of Breast Surgery at Asan Medical Center, and Professor Cha Chi-hwan of Breast Surgery at Hanyang University Hospital, research team led by the 'Long-term oncological outcome of breast-conservating treatment' of breast cancer patients with BRCA mutation It was announced in the May issue.
BRCA1/2 is a tumor suppressor gene that repairs DNA damage in our body, and it is known that mutations in these genes increase the risk of breast cancer. In addition, the mutation of the BRCA1/2 gene has a significant impact on the surgery and treatment of breast cancer.
Previously, Breast-Conservative Treatment (BCT) has become a standard treatment that can replace Mastectomy. However, for patients with BRCA1/2 gene mutations, the lack of safety evidence has pushed them to the back burner in the guidelines.
The study conducted this time conducted a multicenter retrospective cohort study to compare recurrence and survival rates according to surgical methods in high-risk breast cancer patients with BRCA1/2 gene mutations from 2008 to 2015.
The research team collected information on the clinical pathological characteristics and prognosis of 575 breast cancer patients (average age of 42 years) with BRCA1/2 gene mutations, and 389 (66.2%) of the patients included in the study underwent breast preservation treatment and 186 (33.8%) underwent total mastectomy.
Long-term follow-up of recurrence and survival rates between breast preservation treatment and total mastectomy groups showed no significant difference in zone recurrence and distant metastasis and overall recurrence rates in breast cancer recurrence. In addition, the group who underwent breast preservation treatment did not have a higher risk of death than the group who underwent total mastectomy, and multivariate analysis also showed that the surgical method did not affect the prognosis.
Professor Lee Jang-hee of surgery at Ewha Womans University Mokdong Hospital said, "This study is meaningful in that it proved the safety of breast preservation treatment for the first time in the world using propensity score matching (PSM) using statistical techniques in BRCA1/2 gene mutation patients collected from multiple organs in Korea. Various subgroup analysis including BRCA1/2 mutation type, tumor size, lymph node metastasis, histological grade also confirmed that breast preservation treatment can be considered as a breast cancer surgery method." he said.
He then said "This study is a retrospective cohort study, requiring further data collection and planning for prospective studies. Further research will be carried out to provide more accurate evidence in the future."
|
This article was translated by Naver AI translator.
